
Sigrid Therapeutics stock
Last updated
Sigrid Therapeutics is a Swedish clinical biotechnology company developing innovative solutions to prevent and treat lifestyle-related diseases. The company was founded in 2014 by Prof. Tore Bengtsson and Sana Alajmovic with the vision to change the way we manage modern chronic diseases. Their technology, SiPore®, consists of precision-engineered mesoporous silica particles that act in the gut to improve blood sugar control in a safe and effective way. The lead product, SiPore21®, is an oral medical device in clinical development, intended to improve metabolic function in people with prediabetes and new-onset type 2 diabetes. Sigrid Therapeutics is headquartered in Stockholm and is part of Karolinska Innovation's incubator program for promising life science startups in Sweden.
Note: Information on Sigrid Therapeutics is sourced from official channels and public sources unless otherwise stated.
Sigrid Therapeutics new issues and valuations
| Date | Type | Share price | Amount The specific amount raised in this funding round. | Valuation The company's valuation after the funding round was completed (Post-money). |
|---|---|---|---|---|
| Q4 2023 | 20.6 SEK | SEK 43,900,000 | SEK 477,000,000 | |
| Q1 2023 | 20.6 SEK | SEK 2,900,000 | SEK 433,000,000 | |
| Q4 2022 | 20.6 SEK | SEK 7,700,000 | SEK 430,100,000 |
Note: Information on Sigrid Therapeutics's funding rounds, amounts, and valuation is sourced from news media and public sources unless otherwise stated. Information on capital structure is sourced from public company registers unless otherwise stated.
About the company
Business description is not available at this time.
Major Shareholders in Sigrid Therapeutics
| Name | Shares | Capital % |
|---|---|---|
| Ulf Wiinberg consult&invest AB | 5,513,981 | 23.4% |
| M.G.A. HOLDING AKTIEBOLAG | 2,164,139 | 9.2% |
| Nordnet Pensionsförsäkring AB | 723,639 | 3.1% |
| AXC Innovation II AB | 695,000 | 3.0% |
Note: Information on Sigrid Therapeutics's ownership structure is sourced from public company registers and external data providers unless otherwise stated. Source: Eivora (9/8/2025).
Sigrid Therapeutics stock: key facts
Note: Information sourced from official company registrations and public sources unless otherwise stated.
Active market
Settlement follows an established process with third-party verification of payment and share transfer, minimizing counterparty risk for both parties.
Securities shown in the view above are for illustrative purposes only.
News about Sigrid Therapeutics
Sigrid Therapeutics nya vd på plats: Fokus på kommersiell uppskalning
Utnämningen, som offentliggjordes i slutet av januari, var en tydlig signal från Sigrids styrelse. Genom att rekrytera en ledare med djupa rötter i både snabbrörliga konsumentvaror (FMCG) och läkemedelsindustrin, siktar bolaget på att ta marknadsandelar inom den växande nischen för metabol hälsa med sin egenutvecklade SiPore-teknologi. En flygande start Kjærsgaard klev in i Sigrid i […]

Sigrid Therapeutics ingår globalt licensavtal inom munhälsa
Sigrid Therapeutics har ingått ett exklusivt globalt licens- och forskningssamarbete med ett ledande multinationellt konsumenthälsoföretag för att kommersialisera SiPore-teknologin inom konsumentinriktad munhälsa. Avtalet berättigar Sigrid till en förskottsbetalning samt framtida ersättningar kopplade till utvecklingsmål, kliniska framsteg och försäljningsmilstolpar, utöver löpande royalties på nettoförsäljning. Samarbetet etablerar ett ramverk för gemensam forskning och klinisk utvärdering med målet […]

Ozempic-utmanaren Sigrid Therapeutics backas med 45 miljoner – ska växa i USA
Svenska Sigrid Therapeutics får in 45 miljoner kronor för att få spinn på sitt kosttillskott och lansera sin Ozempic-utmanare “Carb fence”.

Buy Sigrid Therapeutics shares
Place a bid on Sigrid Therapeutics shares. View historical prices and access unique company data.
Buy shares in Sigrid TherapeuticsHelp for new buyers
Sell Sigrid Therapeutics shares
Unlock capital from your unlisted holding. Accumeo matches you with buyers and handles settlement through an established process.
Sell shares in Sigrid TherapeuticsHelp for new sellers
Have any questions about buying or selling shares in private companies? Don't hesitate to contact us.
FAQ
Sigrid Therapeutics is an unlisted company, meaning the shares are not traded on any exchange. Instead, transactions take place through direct transfers between parties, known as secondary trading, typically via a specialised platform for unlisted shares such as Accumeo. For larger international companies, investing through fund structures that pool several investors into a single ownership vehicle is also common. This allows smaller minimum investments and opens up access to international companies for non-institutional investors.
Yes, it is possible to buy existing shares in Sigrid Therapeutics through secondary trading. On Accumeo you create a free account, submit an expression of interest with an amount and any conditions, and may then be matched with a seller. Once both parties have signed the customer agreement, a share transfer agreement is drawn up covering price, share count, and settlement date.
Yes, secondary trading is often the only realistic route to liquidity for an unlisted holding before an IPO or acquisition. Via Accumeo you submit an expression of interest with a share count and target price, and a match may be made with a potential buyer. The sale is executed through a share transfer agreement and registered either via Euroclear or directly in the company's share register, depending on how ownership is administered.
Unlisted companies have no continuous share price because there is no continuous exchange trading. The value is instead based on the latest secondary-market trade or on the price per share from the most recent share issuance. Accumeo shows both historical transaction prices and current bid/ask quotes, providing a combined reference point for pricing.
The value of an unlisted share is most often based on the latest trade — the price buyer and seller agreed in a transaction — or on the latest funding round, where the company and its investors agreed a price for the newly issued shares. These are the reference points shown on Accumeo's platform. It is, however, important to form your own view of value by examining the company's prospects. Financial reports, growth opportunities, market position, and comparable transactions in the sector all help to build a better picture of how the business may develop. Useful information can be found on the company's own website, via Accumeo's platform, and on services like allabolag.se.
No, Sigrid Therapeutics is an unlisted company and its shares are not traded on the Stockholm Stock Exchange, NYSE, or any other regulated marketplace. Shares are instead traded through secondary trading between investors, typically via a specialised platform such as Accumeo.
Disclaimer: The information in this FAQ is provided for informational purposes only and does not constitute an offer to buy or sell securities, a solicitation of such an offer, or investment advice. Accumeo has no commercial relationship with the companies whose securities are mentioned. Independent advice should be obtained before making any investment decision.
Other companies you may be interested in
Start exploring unlisted shares today
Join 5,000+ investors already trading unlisted shares. Create an account in 2 minutes with BankID — completely free.








